Open AccessPreclinical characterization of CPL302-253, a selective inhibitor of PI3Kδ, as the candidate for the inhalatory treatment and prevention of Asthma
Author(s) -
Paweł Gunerka,
Kamila Gala,
Martyna Banach,
Jakub Dominowski,
Joanna Hucz-Kalitowska,
Krzysztof Mulewski,
A. Hajnal,
Endre G. Mikus,
Damian Smuga,
Marcin Zagozda,
Krzysztof Dubiel,
Jerzy Pieczykolan,
Beata M. Zygmunt,
Maciej Wieczorek
Publication year - 2020
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0236159
Subject(s) - asthma , medicine , inhalation , population , immunology , in vivo , pharmacology , anesthesia , biology , environmental health , microbiology and biotechnology
Asthma is a common chronic inflammatory disease. Although effective asthma therapies are available, part of asthmatic population do not respond to these treatment options. In this work we present the result of development of CPL302-253 molecule, a selective PI3Kδ inhibitor. This molecule is intended to be a preclinical candidate for dry powder inhalation in asthma treatment. Studies we performed showed that this molecule is safe and effective PI3Kδ inhibitor that can impact many immune functions. We developed a short, 15-day HDM induced asthma mouse model, in which we showed that CPL302-253 is able to block inflammatory processes leading to asthma development in vivo .